Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases

Authors Information
Article Notes and Dates
To Cite : Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, et al. Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases, Hepat Mon. 2013 ;13(9):e11721. doi: 10.5812/hepatmon.11721.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Introduction
2. Case Presentation
3. Conclusions
  • 1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917[DOI]
  • 2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42(5): 1208-36[DOI][PubMed]
  • 3. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009; 10(1): 25-34[DOI]
  • 4. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011; 140(5): 1410-26[DOI][PubMed]
  • 5. Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology. 2013; 57(3): 1068-77[DOI][PubMed]
  • 6. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005; 27(1): 23-44[DOI][PubMed]
  • 7. Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol. 2010; 17(1): 59-63[PubMed]
  • 8. Emmenegger U, Kerbel RS. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie. 2007; 30(12): 606-8[DOI][PubMed]
  • 9. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6): 423-36[DOI][PubMed]
  • 10. Brandi G, de Rosa F, Bolondi L, Agostini V, Di Girolamo S, Nobili E, et al. Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori. 2010; 96(6): 1028-30[PubMed]
  • 11. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004; 101(3): 578-86[DOI][PubMed]
  • 12. Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 2010; 17(12): 3137-44[DOI][PubMed]
  • 13. Ballardini P, Marri I, Margutti G, Aliberti C, Benea G, Manfredini R. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma. Tumori. 2010; 96(5): 768-70[PubMed]
  • 14. Maraveyas A, Lam T, Hetherington JW, Greenman J. Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer. 2005; 92(8): 1588-90[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check